Almirall acuerda comercializar fármaco de Nycomed en España

MADRID, 5 may (Reuters) - Almirall ALM.MC dijo el jueves que ha acordado con Nycomed la comercialización en España de un antiinflamatorio para pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC).

El acuerdo contempla un pago de Almirall a Nycomed, aunque no se ha desvelado su importe.

Almirall dijo que espera lanzar el fármaco, denominado roflumilast, a lo largo de este año.


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.